

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Doraiswamy, Anupama

eRA COMMONS USER NAME (credential, e.g., agency login): doraisan

POSITION TITLE: Assistant Professor of Medicine, Attending Physician, Hematologic Malignancies/Bone Marrow Transplant

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
Medical School: Byramjee Jeejee Bhoy Medical College, University of Pune, Pune, Maharashtra, India	MBBS	12/1995	Medicine
Internship: Chennai Medical College, University of Madras, Chennai, Tamil Nadu, India	MBBS	01/1997	Medicine
Internal Medicine Residency, Johns Hopkins University/Sinai Hospital of Baltimore, Baltimore, MD	MD	06/2009	Internal Medicine
Chief Residency-Internal Medicine, Johns Hopkins University/Sinai Hospital of Baltimore, Baltimore, MD	MD	06/2010	Internal Medicine
Fellowship – Hematology & Oncology, Robert Wood Johnson Medical School/UMDNJ, New Brunswick, NJ	MD	6/2013	Hematology-Oncology

A. Personal Statement

I am an Assistant Professor of Medicine, and am an attending physician in hematologic malignancies, section of Blood disorders and Bone Marrow Transplantation. My expertise focuses on acute leukemias and myeloid malignancies. I focus on clinical research and am the site Principal Investigator for several key clinical trials in the field of acute leukemias. I am a co-investigator for a novel preclinical study of Bone Morphogenetic Protein (BMP) inhibitors (in combination with BCL-X inhibitors on AML cell lines expressing TP53 and RAS mutations). We have a Pilot internal grant funding for this project. Our original research article is published in Cell Communication and Signaling, showing effect of BMP inhibitors in combination with mitochondrial targeting agents on AIF non-caspase mediated cell death on LKB-1 expressing lung cancer cell lines. These efforts strive to bring translational science from the lab to the clinic, to bring promising new therapies to the patients we serve. I am a Principal Investigator for several industry sponsored clinical trials, Phase I, II and III, focusing on acute leukemia. I am the PI for a novel dual IDH inhibitor Phase 1 study in hematologic malignancies. I strived to initiate this study at R-CINJ and successfully helped enroll the first patient in the United States from our center. I am the first author on the preclinical abstract of this study, published in ASH abstracts 2021. I am the first author on an invited review on the role of old and new immunotherapies, including bispecific antibodies, CART and autologous transplant in relapsed

refractory non-Hodgkin lymphomas, published in *Current Hematologic Malignancy Reports*. I have submitted a proposal to start a novel, "CHIP" (clonal hematopoiesis of indeterminate potential) clinic program at R-CINJ. Given several clinical implications of CHIP mutations including cardiovascular risks, thrombosis and evolution into heme malignancies, and an impact on their survival with early detection. I was an invited speaker on Hematologic Malignancies - Leukemia session, at the recent ASCO Direct Philadelphia Conference, Best of ASCO, July 23-24, 2022. I enjoyed sharing my expertise in AML and myeloid malignancies in this national post ASCO meeting. I serve as the Medical Director for hematologic malignancies clinic and infusion services, since 2020 and strive to sure great patient experience and excellent medical care. I serve on the ambulatory operations committee, which meets every 2 weeks to discuss, design and improve clinical operations. I also serve on the Malignant Hematology Council, meeting weekly with malignant hematology nursing leadership and practice management, to continue to improve outpatient workflow and efficiency, in a growing practice. I also serve on the hematologic malignancy tumor board planning committee, which strives to continue highly quality multidisciplinary tumor boards.

B. Positions, Scientific Appointments, and Honors

Positions, Scientific Appointments

July 2006 – June 2009: Member, American College of Physicians

June 2009 – June 2010: Chief Resident Internal Medicine Johns Hopkins University/Sinai Hospital of Baltimore, Baltimore, MD

September 2013 – November 2015: Assistant Professor of Medicine, Division of Hematology, Rutgers RWJ Medical School, Rutgers Medical Group, Rutgers University, New Brunswick, NJ

January 2014– November 2015: Course Director, Second year medical school class, Hematology Oncology, Rutgers RWJ Medical School, Rutgers University, Piscataway, NJ

December 2016 – October 2018: Assistant Professor of Medicine, Department of Hematology & Oncology Cleveland Clinic, Florida/Case Western University, Cleveland, Ohio

January 2020 – Current: Assistant Professor of Medicine, Division of Blood Disorders, Rutgers RWJ Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

October 2020– Current: Medical Director, Clinic and Infusion services, Division of Blood Disorders, Rutgers RWJ Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

September 2013 – November 201, January 2020– Current: Member, Core Competency Committee, Hematology oncology fellowship program, Rutgers RWJ Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

Honors

Highest Scorer – Internal Medicine In-Service Exam, 1st year Internship Johns Hopkins University / Sinai Hospital of Baltimore, Baltimore, MD, June 2007

First Prize – Clinical Cancer Research Oral presentation: Hodgkin's disease in a patient with Systemic Mastocytosis at Oncology Society of New Jersey scientific forum, May 8, 2013

Represented Maryland State at the 2007 National American College of Physicians meet in San Diego for Doctor's Dilemma Quiz

Trained and led Maryland Internal Medicine Resident team to represent the state at the 2010 National American College of Physicians meet in Toronto for Doctor's Dilemma Quiz

C. Contributions to Science

Principal Investigator (PI)

1. SELGI-00005, Selexys Pharmaceuticals, Industry sponsored, A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind 12-month Study to Assess Safety and Efficacy of SelG1 in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises, "SUSTAIN" Study, 10/1/2013 – 10/15/2015, Closed.
2. Hutchison MediPharma Limited, Industry Sponsored, A Phase 1, Open- Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations, 2020-306-GLOB1, 2/5/2021 – Current. Accrual ongoing.
3. EA9181, ECOG study, A Phase III Randomized Trial of Steroids +Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia in Adults, 4/15/2021 – Current. Accrual ongoing.
4. ARO-021, AROG Pharmaceuticals, Industry Sponsored, A Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia, 5/1/2021 – Current. Closed for accrual.
5. A single institutional retrospective study of patient characteristics, treatment patterns, and outcomes in adult patients with Philadelphia-positive B-cell acute lymphoblastic leukemia, 6/21/2021 – Current. IRB approved. Data collection in process.
6. Gilead Sciences, Industry sponsored, A Phase 3, Randomized, Double- Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy, 10/2022 – Current. Accrual ongoing.

Co-Investigator

1. Pilot Grant: Internal Funding. Preclinical study of BMP antagonists with and without BCL-2 and BCL-X inhibitors on AML cell lines, including TP53 and RAS mutant AML cell lines.
2. Multicenter Retrospective studies about Frontline Therapies of Classical Hodgkin Lymphoma including Brentuximab Vedotin and chemotherapy. In progress.

Articles/Abstracts:

1. Review Article: Anupama Doraiswamy MD, Mansi Shah MD, Rajat Bannerji MD, PhD. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T-cells and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Published in Current hematologic malignancy reports, Vol.16(1), pp.72-81; 02/2021, PMID: 33619641
2. Original Article: Arindam Mondal, Jacques Roberge, John Gilleran, Youyi Peng, Dongxuan Jia, Moumen Akel, Anupama Doraiswamy, John Langenfeld. Bone morphogenetic protein inhibitors and mitochondrial targeting agents synergistically induce Apoptosis-Inducing Factor (AIF) caspase-independent cell death in lung cancer cells. Published in Cell Communication and Signaling, 27 Jun 2022, 20(1):99, PMID: 35761398
3. Doraiswamy. A, Goldstein. D, Schaar,D, Bannerji.R. Hodgkin's disease in a patient with Systemic Mastocytosis. Oral Presentation, Clinical Cancer Research in New Jersey; Oncology Society of New Jersey, Newark, NJ, May 2013; Abstract#5. (Awarded first prize for best oral presentation).

4. Doraiswamy. A, Vijayvel Jayaprakash, Marek Kania, Marjo Hahka-Kemppinen, ZhaoYang, Mark Rudinski, Farhad Ravandi, A Phase 1, Open-Label, Multicenter Study of HMPL- 306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations, Published in Blood (2021) 138 (Supplement 1): 4438.
5. Invited Speaker for ASCO Direct Philadelphia Conference, Best of ASCO, July 23-24, 2022, on Hematologic Malignancies-Leukemia session.